

November 24, 2021

To: All Concerned Parties

Company Name: Solasia Pharma K.K.
Representative: Yoshihiro Arai, President & CEO
(Code number: 4597, TSE Mothers Section)
Contact: Toshio Miyashita, CFO, Director
Tel: 81-3-5843-8045
URL: <https://solasia.co.jp/en/>

Solasia's Partner, Isofol Receives FDA Fast Track Designation for arfolitixorin (SP-05) in Advanced Colorectal Cancer

Isofol Medical AB (publ) (STO: ISOFOL), Solasia's partner announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for the development of the drug candidate arfolitixorin (SP-05), the stabilized and biologically active pure form of folate ([6R]-MTHF), for treatment of patients with metastatic colorectal cancer (mCRC).

For more information, please refer to the Isofol's website. [Link](#)

###